Antibody to E1 peptide of hepatitis C virus genotype 4 inhibits virus binding and entry to HepG2 cells in vitro.
OBJECTIVE
To analyze the neutralizing activity of antibodies against E1 region of hepatitis C virus (HCV). Specific polyclonal antibody was raised via immunization of New Zealand rabbits with a synthetic peptide that had been derived from the E1 region of HCV and was shown to be highly conserved among HCV published genotypes.


METHODS
Hyper-immune HCV E1 antibodies were incubated over night at 4 degree Celsius with serum samples positive for HCV RNA, with viral loads ranging from 615 to 3.2 million IU/ mL. Treated sera were incubated with HepG2 cells for 90 min. Blocking of viral binding and entry into cells by anti E1 antibody were tested by means of RT-PCR and flow cytometry.


RESULTS
Direct immunostaining using FITC conjugated E1 antibody followed by Flow cytometric analysis showed reduced mean fluorescence intensity in samples pre-incubated with E1 antibody compared with untreated samples. Furthermore, 13 out of 18 positive sera (72%) showed complete inhibition of infectivity as detected by RT-PCR.


CONCLUSIONS
In house produced E1 antibody, blocks binding and entry of HCV virion infection to target cells suggesting the involvement of this epitope in virus binding and entry. Isolation of these antibodies that block virus attachment to human cells are useful as therapeutic reagents.
El-Awady
Mostafa K
MK
Department of Biomedical Technology, National Research Center, Dokki, Cairo, Egypt. mkawady@yahoo.com
Tabll
Ashraf A
AA
Atef
Khaled
K
Yousef
Samar S
SS
Omran
Moataza H
MH
El-Abd
Yasmin
Y
Bader-Eldin
Noha G
NG
Salem
Ahmad M
AM
Zohny
Samir F
SF
El-Garf
Wael T
WT